Are Analysts Bearish Nevro Corp. (NYSE:NVRO) After Last Week?

May 16, 2018 - By Migdalia James

Nevro Corp. (NYSE:NVRO) Ratings Coverage

Among 7 analysts covering Nevro (NYSE:NVRO), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Nevro has $110.0 highest and $83 lowest target. $94.80’s average target is 21.15% above currents $78.25 stock price. Nevro had 10 analyst reports since December 12, 2017 according to SRatingsIntel. The company was maintained on Thursday, February 22 by Canaccord Genuity. Wells Fargo downgraded Nevro Corp. (NYSE:NVRO) on Tuesday, May 8 to “Hold” rating. Canaccord Genuity maintained it with “Buy” rating and $11000 target in Thursday, April 12 report. Canaccord Genuity maintained it with “Buy” rating and $102 target in Tuesday, May 8 report. The firm has “Buy” rating given on Tuesday, January 23 by William Blair. On Tuesday, December 12 the stock rating was maintained by BMO Capital Markets with “Buy”. Canaccord Genuity maintained Nevro Corp. (NYSE:NVRO) rating on Tuesday, January 16. Canaccord Genuity has “Buy” rating and $110.0 target. JMP Securities maintained Nevro Corp. (NYSE:NVRO) rating on Tuesday, May 8. JMP Securities has “Market Outperform” rating and $105 target. On Tuesday, May 8 the stock rating was downgraded by Northland Capital to “Hold”. Below is a list of Nevro Corp. (NYSE:NVRO) latest ratings and price target changes.

08/05/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $110 New Target: $102 Maintain
08/05/2018 Broker: Northland Capital Rating: Hold Downgrade
08/05/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $120 New Target: $105 Maintain
08/05/2018 Broker: Wells Fargo Rating: Hold New Target: $84.0000 Downgrade
12/04/2018 Broker: Canaccord Genuity Rating: Buy New Target: $110.0000 Maintain
04/04/2018 Broker: Goldman Sachs Rating: Neutral New Target: $83 Initiates Coverage On
22/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $110.0 Maintain
23/01/2018 Broker: William Blair Rating: Buy Maintain
16/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $110.0 Maintain
12/12/2017 Broker: BMO Capital Markets Rating: Buy New Target: $100.0 Maintain

The stock increased 2.27% or $1.74 during the last trading session, reaching $78.25. About 535,291 shares traded or 29.08% up from the average. Nevro Corp. (NYSE:NVRO) has declined 8.11% since May 16, 2017 and is downtrending. It has underperformed by 19.66% the S&P500.

Nevro Corp., a medical device company, focuses on providing products for the patients suffering from chronic pain in the United States and internationally. The company has market cap of $2.35 billion. It develops and commercializes the Senza spinal cord stimulation system, an evidence neuromodulation platform for the treatment of chronic pain. It currently has negative earnings. The firm sells its products through its direct sales force, and a network of sales agents and independent distributors.

More important recent Nevro Corp. (NYSE:NVRO) news were published by: Prnewswire.com which released: “Nevro Recognized as a “Best Place to Work” in the Bay Area” on May 14, 2018, also Seekingalpha.com published article titled: “Nevro’s (NVRO) CEO Rami Elghandour on Q1 2018 Results – Earnings Call Transcript”, Streetinsider.com published: “After-Hours Stock Movers 05/07: (FRED) (VECO) (FN) Higher; (NVRO) (INWK) (HTZ) Lower (more…)” on May 07, 2018. More interesting news about Nevro Corp. (NYSE:NVRO) was released by: Nasdaq.com and their article: “Recent Analysis Shows Paycom Software, American Renal Associates, Knowles, Timken, Nevro, and Unisys Market …” with publication date: May 15, 2018.

Nevro Corp. (NYSE:NVRO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: